BioInformant

Your Global Leader in Stem Cell Market Research

Home » CYP-001

Cynata Introduces Critical Innovation into MSC Manufacturing

By

In the context of cell therapy, product innovation is the introduction of a cellular product that is new or has significantly improved characteristics or intended uses. Over the past decade, a great deal of attention has been given to cell therapy product innovation, as demonstrated by the thousands of cell therapy products that have now entered clinical trials worldwide.

In contrast, process innovation refers to the implementation of a new or significantly improved production or delivery method. In the context of cell therapy, process innovation has received much less attention from the marketplace. [Read more…]

Patient Treatment Commences in Cynata’s World First Clinical Trial (CYP-001)

By

  • First patient with steroid resistant acute graft-versus-host disease (GvHD) treated in Cynata’s phase 1 clinical study of its mesenchymal stem cell (MSC) product, CYP-001
  • World first clinical trial using a MSC therapeutic product derived from an induced pluripotent stem cell sourced from a single blood donation from one donor
  • Transition into active clinical trials cements Cynata’s world leading position in the development and commercialisation of second generation stem cell products
  • Partnership with Fujifilm for the commercialisation of CYP-001; trial commencement accelerates this target

[Read more…]

Cynata Therapeutics Secures $6M in Capital Raise, $10M with Payment from FUJIFILM

By

Cynata Successfully Completes Capital Raising

Cynata TherapeuticsMelbourne, Australia; 23 January 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has successfully completed a placement of approximately 9.23 million fully-paid ordinary shares at a price of $0.65, for gross proceeds of A$6.0 million before costs (“Placement”). The Placement was made to existing and new sophisticated and institutional investors. Settlement of the Placement, which was heavily over-subscribed, is expected to occur on or about 27 January 2017 with the shares to be issued on 30 January 2017. The Placement shares will be issued under Cynata’s existing placement capacity under Listing Rules 7.1 and 7.1A, and accordingly will not require shareholder approval.  [Read more…]

Cynata Inks Deal with FUJIFILM, $3.97M Plus Potential Payments of $60M+

By

Cynata and FUJIFILM Sign Development and Commercialisation Partnership Agreement

  • Fujifilm takes A$3.97 million strategic equity stake in Cynata
  • Parties to collaborate on the further development and commercialisation of Cynata’s lead Cymerus™ therapeutic MSC product CYP-001 for graft-versus-host disease (GvHD)
  • Potential future upfront and milestone payments in excess of A$60 million
  • Double-digit royalties on CYP-001 product net sales
  • Strategic relationship for potential future manufacture of CYP-001 and certain rights to other Cynata technology

[Read more…]

UK Regulatory Authority Approves Cynata Therapeutics’ Phase I GvHD Clinical Trial

By

  • UK regulatory authority MHRA approves Phase 1 trial with Cymerus(TM) MSCs
  • World first clinical trial with allogeneic iPSC-derived product
  • Major milestone for stem cell therapeutics and regenerative medicine
  • Cements Cynata’s global leadership in second generation MSC therapeutics

[Read more…]

BioInformant's World-Class Clients